This trial is evaluating whether Olaparib will improve 1 primary outcome in patients with Prostate Cancer. Measurement will happen over the course of 1 year.
This trial requires 5 total participants across 2 different treatment groups
This trial involves 2 different treatments. Olaparib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
The prognosis is poor in patients with pT3a/b disease only. However, these patients have a much better long-term survival compared to patients with T3 disease, irrespective of pathological stage. Patients with advanced disease do better than previously assumed.
The antiproliferative activity of olaparib was demonstrated in prostate cancer cell lines. Recent findings were not caused by inhibition of the MEK/ERK1/2 signaling pathway in vitro.
If not diagnosed very early [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) progresses slowly; if diagnosed early, the average patient survives five years. If diagnosed a year or two after diagnosis, the average survival is just one year. And if diagnosed a few months or a few years after diagnosis the average survival is five or six months. Current guidelines (US/UK) state that prostate-specific antigen screening with prostate-specific antigen testing to detect clinically localised prostate cancer or prostate cancer with clinical or surgical stage T1c cancer (no biochemical recurrence for N.B. these early staged conditions will usually have favorable prognosis) should begin at age 70 (60, 63); when this age is approached (age 75, 70) use a one time screening PSA test.
Treatment for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) depends on the type of cancer and how advanced it is. Common options include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy, or a combination of these.
Recent findings shows the total number of cases in the U.S. was around 250,000 new cases a year and more than half of these cases are African American. It also shows a decline in incidence from 1979 to 1999 and a fall in stage at diagnosis, most likely a reflection of prostate specific antigen screening over the years.
The National Comprehensive Cancer Network has developed a comprehensive and useful website with downloadable downloadable clinical tools for diagnosis, surveillance and treatment. It can be used to define and manage patients with early stage [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). By using this information, patients and health care providers can make informed decisions about early prostate cancer detection and treatment. It can also be used to help patients plan for treatment that could improve outcomes and quality of life.
It is difficult to differentiate signs and symptoms of PCa from those of BPH. However, the risk factors for PCa are also risk factors for BPH. The signs and symptoms of PCa can be separated into three main groups: signs present in the symptomatic presentation of the disease, signs indicative of the condition and signs indicative of the progression of BPH to PCa. The presence of one or more of these three signs is highly suggestive of PCa.
This is the first study to report OLA treatment in a large, prospective, Phase III study (Olaparib in Prostate and Ovarian Cancer (Olaparib in POC) study) of patients with metastatic and/or [recurrent prostate cancer](https://www.withpower.com/clinical-trials/recurrent-prostate-cancer). Results so far have demonstrated a significant improvement in progression-free survival and overall survival. The median duration of response was 20.4 weeks and the median progression-free survival was 13.3 weeks. The 1-year and 2-year survival rates are 96.3% and 82.9% with progression-free survival being 50.0% and 35.6% with overall survival being 66.0% and 51.9%.
For most patients the [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is localized at the time of diagnosis. Prostatic cancer can be fatal in approximately 2.5% of patients who suffer from late metastatic disease. In one third of patients with metastatic disease, prostate cancer does not progress after first-line treatment. For most men with metastatic disease, prostate cancer is lethal, however, one year after androgen deprivation therapy, if no chemotherapy is given, the cause of death is almost always due to other causes; and prostate cancer-related death usually occurs 2 to 3 years after the onset of metastatic disease. Thus, prostate cancer is usually not life-threatening.
In the last 5 years a lot of new data, not only in the treatment but also in the molecular biology of prostate cancer were published. Despite this progress our knowledge still very much depends on the availability of a cure for prostate cancer. At the end of this review is a list of important publications relevant to this subject.
The treatment-related toxicities of olaparib are as high as in phase II trials, but the common treatment-related adverse events in patients of the LEE011 study were different. Patients with advanced NSCLC should not take olaparib concomitantly with cytotoxic compounds such as docetaxel unless recommended by a physician.
Overall, the most commonly cited reasons that patients cited, in order of frequency, for not participating in clinical trials were that they feared the trial would lead to more invasive testing and would not work for them. Future research and development efforts should focus on developing less invasive clinical trials for prostate cancer.